B群脑膜炎奈瑟球菌感染的流行现状及耐药状况  

Epidemic status and drug resistance of group B Neisseria meningitidis

作　　者：车鑫仁[1] 刘艳[1] 许玉洋[1] 张学潮[1] 张小平[1] 杜渐[1] 王骏[1] 顾雯雯[1] 江伟 Che Xinren;Liu Yan;Xu Yuyang;Zhang Xuechao;Zhang Xiaoping;Du Jian;Wang Jun;Gu Wenwen;Jiang Wei(Department of Expanded Program on Immunization,Hangzhou Center for Disease Control and Prevention,Hangzhou 310021,China)

机构地区：[1]杭州市疾病预防控制中心免疫预防所,310021

出　　处：《国际流行病学传染病学杂志》2021年第5期399-404,共6页International Journal of Epidemiology and Infectious Disease

基　　金：杭州市科技计划引导项目(农业与社会发展)(20171226Y25)。

摘　　要：随着多种脑膜炎奈瑟菌(Nm)菌种对应疫苗的问世,各型流行性脑脊髓膜炎(简称"流脑")的流行情况发生着变化,近几年B群Nm构成增多,健康人群中B群Nm带菌者占比上升,我国部分地区也出现由于密切接触B群Nm带菌者从而致病的情况。了解B群Nm感染的流行现况,明确B群株耐药情况,更新预防性治疗药品方案,可有效降低流脑的发病率和死亡率。本文针对B群Nm感染的流行和耐药现状作一综述,为防治提供参考。With the development of various vaccines for Neisseria meningitides(Nm),the epidemic of meningococcal meningitis is changing.In recent years,the composition of B group Nm increases,and the proportion of B group Nm carriers in healthy people increases.Patients due to close contact with group B Nm carriers have also occurred in some areas of China.Therefore,it is very important to understand the epidemic of group B Nm,clarify the drug resistance of dominant epidemic group B and update the preventive drug regimen,so as to effectively reduce the morbidity and mortality of meningitis.In this paper,epidemic status and drug resistance of group B Nm are summarized to provide basis for Nm control and prevention.

关 键 词：奈瑟球菌 脑膜炎 血清B群 流行性脑脊髓膜炎 流行病学 耐药 

分 类 号：R515.2[医药卫生—内科学] R181.3[医药卫生—临床医学]